GLOBAL DRUG OF ABUSE (DOA) TESTING MARKET www.vynzresearch.com
enquiry@vynzresearch.com
Industry Overview  Drug of Abuse (DOA) testing is the clinical detection of one or more drugs within the human system, by sample testing. This is done to provide clinical intervention or for monitoring of illegal drug intake. Global DOA testing market was poised at USD 4,938.6 million in 2017. The testing for DOA requires products such as immunoassay analyzers, chromatography instruments, breath analyzers, rapid test kits, and assay kits & reagents. The rapid test kits are driving the growth of the DOA testing market and are the estimated to hold the largest share in 2017. Explore Full Report Description at: https:// www.vynzresearch.com/healthcare/drug-of-abuse-doa-testing-marke t
market segmentation  Among the various products being used in DOA testing, the rapid test kits forms the largest contributor to the industry. This category high demand is due to the easy availability and access for on the spot drug testing. The rapid test kits as per its name also presents output in short time thereby has higher demand in comparison to the other product category. However, the breath analyzers are estimated to grow at a fast rate with a CAGR of 9.7% during the forecast period.
Geographic Overview  Geographically, North America account for the largest share in the DOA testing market, globally. This contribution is due to the adaptation of technologically advanced products for DOA testing, increased demand for illicit drugs in the region, large scale drug trafficking, and the increasing government initiative to spread awareness against DOA. Moreover, the DOA testing industry is expected to be witness fastest growth in Asia-Pacific.
Competition among key players The major player in the global DOA testing market include Danaher Corporation, Siemens AG, Merck KGaA, Drägerwerk AG & Co. KGaA, bioMérieux S.A., Waters Corporation, Roche Holding AG, Quest Diagnostics Inc., Laboratory Corporation of America Holdings, Alere Inc., Abbott Laboratories, ThermoFisher Scientific Inc., Express Diagnostics Int'l, Inc., Randox Laboratories Ltd., Psychemedics Corporation, Bio-Rad Laboratories, Inc., and Sonic Healthcare Ltd. The leading players through acquisitions are attaining competency and larger market share in the global DOA testing industry. For example in January 2018, ACM Global Laboratories, an affiliate of Rochester Regional Health announced the strategic acquisition of DrugScan, Inc. and DSI Medical Services, Inc. The acquisition was made to establish laboratory service portfolio and drug testing capabilities.
THANK YOU!
https:// www.vynzresearch.com/healthcare/drug-of-abuse-doa-testing-market/reques t-sample enquiry@vynzresearch.com US/Canada Toll-Free: 1-888-253-
www.vynzresearch.com